SCHEMBL30698306

SCHEMBL30698306

COc1cc2ncc(-c3nc(N[C@@H]4CCCN(C(=O)OC(C)(C)C)C4)c(F)cc3F)n2nc1N1CCCS1(=O)=O

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PIK3CD O00329 2/20 0.37
▸ NRAS P01111 1/20 0.36
▸ FLT3 P36888 1/20 0.36
▸ PIM1 P11309 2/20 0.36
▸ PIM2 Q9P1W9 2/20 0.36
▸ EGFR P00533 5/20 0.36
▸ ITK Q08881 2/20 0.36
▸ BTK Q06187 2/20 0.36
▸ TRPV1 Q8NER1 1/20 0.34
▸ USP30 Q70CQ3 1/20 0.34
▸ EHMT2 Q96KQ7 1/20 0.34
▸ SCN9A Q15858 1/20 0.34
▸ ALK Q9UM73 1/20 0.34
▸ NTRK1 P04629 1/20 0.34
▸ PIK3CA P42336 1/20 0.34
▸ NSD2 O96028 1/20 0.34
▸ CFTR P13569 1/20 0.34
▸ DNMT3A Q9Y6K1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31000234 0.91 CDK4 (0.38) PIK3CDEGFRITKBTKTRPV1
SCHEMBL30698291 0.86 PIK3CD (0.40) PIK3CDNRASFLT3PIM1PIM2
SCHEMBL30698325 0.83 NRAS (0.37) PIK3CDNRASFLT3PIM1PIM2
SCHEMBL30698357 0.83 FLT3 (0.50) NRASFLT3
SCHEMBL30698318 0.83 PIK3CD (0.40) PIK3CDNRASFLT3PIM1PIM2
SCHEMBL31639286 0.79 KMT2A (0.39) PIK3CDPIM1PIM2BTKUSP30
SCHEMBL31639179 0.78 PIK3CD (0.42) PIK3CDPIM1PIM2EGFRITK
SCHEMBL31639188 0.78 SCN9A (0.39) PIK3CDPIM1PIM2BTKUSP30
SCHEMBL31639374 0.78 PIK3CD (0.43) PIK3CDEHMT2SCN9APIK3CANSD2
SCHEMBL27331054 0.78 NRAS (0.39) NRASFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250368648-A1 MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2025-12-04 — — US disclosed
EP-4540248-A2 MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF Children's Hospital Medical Center (US) 2025-04-23 — — EP disclosed
WO-2023245123-A2 MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2023-12-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250368648-A1 MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF FLT3, IRAK1, IRAK2 PIK3CD 187/4885NRAS 371/4885FLT3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback